Biovitrum Ab (publ)

Other

Proximagen Limited

Tom Fleck

Magnus Cernerud

Alexander Paptchikhine

Margit Pelcman

Alf Nygren

Emma Andersson

Helena Lundström

Claes Löfström

Bruce Fleck, Legal Representative

The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R-Rare each independently selected from the group consisting of hydrogen, halogen, C-C-alkyl, C-C-alkoxy, and di-C-C-alkylamino-C-C-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.

Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases

(2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof

Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine

Stable acid addition salts of certain 2,3-disubstituted pyrazine compounds that are selective for the 5-HT2c receptor and therapeutically active in the central nervous system are described.

Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine

Growing community of inventors

Scotts, MI, United States of America

Tom Fleck